tbuckley/cabot-search huggingface dataset:
Clinicians' Forensic Interpretations of Fatal Gunshot Wounds Often Miss the Mark
Authors: Teri Randall
Journal: JAMA (1993)

THE ODDS that a trauma specialist will correctly interpret certain fatal gunshot wounds are no better than the flip of a coin, according to a recent study at a level 1 trauma center. The study, which looked at single, perforating (exiting) gunshot wounds and multiple gunshot wounds, found that trauma specialists made errors in 52% of the cases, either in differentiating the entrance and exit wound, or in determining the number of bullets that struck the victim. Investigators at the Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, NC, compared the postmortem findings of a board-certified forensic pathologist with the medical records of emergency medicine physicians, trauma surgeons, and neurosurgeons. The study is the first to quantify the forensic acumen of these specialists, says Vincent DiMaio, MD, a forensic pathologist and editor of<i>The American Journal of Forensic Medicine and Pathology</i>. The study's coauthors, Kim Collins, MD, a fourth-year
ADRs
Authors: E.G. McQueen
Journal: JAMA (1975)

<h3>To the Editor.—</h3> In relation to the editorial by Dr. John C. Ballin (229:1097, 1974), the results of a survey of adverse drug reactions in a general hospital in New Zealand carried out in 1972 may be of some relevance. The data relate to all admissions to Dunedin Hospitals and are based on an intensive monitoring of reactions over a 12-month period.<sup>1,2</sup>During this time, there were 17,586 admissions to all wards and a total of 600 deaths, of which 11 were considered attributable to or substantially contributed to by adverse drug reactions. Adverse reaction mortality, therefore, was 0.06% of all admissions or 1.8% of total deaths. The population under scrutiny was a relatively small one, but the data may be helpful by reason of their derivation from the whole intake of a general hospital rather than selected wards.
THE SYMPTOMATOLOGY OF DISTURBANCES IN ACID-BASE BALANCE
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 2620: Global epigenetic regulation of gene expression and tumor suppression in T-cell leukemia by Ikaros
Authors: Yali Ding, Bo Zhang, Jonathon L. Payne, Kimberly J. Payne, Chunhua Song, Chandrika Gowda, Soumya Iyer, Pavan K. Dhanyamraju, Dhimant Desai, Suming Huang, Feng Yue, Sinisa Dovat
Journal: Cancer Research (2019)

Abstract Ikaros encodes a DNA-binding zinc finger protein that functions as a tumor suppressor. Loss of Ikaros function results in the development of high-risk B-cell and T-cell acute lymphoblastic leukemia. Previous studies suggested that Ikaros controls expression of its target genes via chromatin remodeling, and by forming complexes with the histone deacetylase, HDAC1. However, the mechanisms through which Ikaros regulates the global epigenetic signature in leukemia is unknown. We studied the role of Ikaros in regulating tumor suppression in Ikaros-defficient T-cell acute lymphoblastic leukemia (T-ALL) cells. The re-introduction of Ikaros at physiological levels via retroviral transduction into T-ALL cells, results in a cessation of cellular proliferation and cell cycle arrest within 4 days. To determine the dynamics of Ikaros-mediated epigenetic regulation of gene expression in T-ALL, we performed ChIP-seq of Ikaros, HDAC1, and histone modifications, along with microarray and ATAC-seq in wild-type T-ALL (that lacks Ikaros), and during each of 3 days following the re-introduction of Ikaros. Our results demonstrated that Ikaros directly regulates the global epigenomic landscape including genome wide de novo formation of enhancers in T-ALL. Further analysis showed that Ikaros induces the re-distribution of HDAC1 via direct recruitment of HDAC1 to promoter and enhancer regions of different target genes resulting in their transcriptional repression. Expression analysis identified a large number of novel signaling pathways that are directly regulated by Ikaros and HDAC1, and are responsible for the cessation of proliferation and the cell cycle arrest of T-ALL cells. Our results identified novel functions of Ikaros in the epigenetic regulation of gene expression and tumor suppression in T-ALL. Citation Format: Yali Ding, Bo Zhang, Jonathon L. Payne, Kimberly J. Payne, Chunhua Song, Chandrika Gowda, Soumya Iyer, Pavan K. Dhanyamraju, Dhimant Desai, Suming Huang, Feng Yue, Sinisa Dovat. Global epigenetic regulation of gene expression and tumor suppression in T-cell leukemia by Ikaros [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2620.
The Diabetic A B C: A Practical Book for Patients and Nurses.
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
INFLUENCE OF INANITION ON THE INFECTION WITH THE COLON BACILLUS.
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE 58TH ANNUAL CONGRESS ON MEDICAL EDUCATION
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Errata
Journal: Diabetes Care (2009)

In the RESEARCH DESIGN AND METHODS subsection "Statistical analysis" in the print version of the article listed above, the recitation of "Wilcoxon signed-rank test" is incorrect and should be "Wilcoxon rank-sum test."The authors used the Wilcoxon rank-sum test, and the results reported are correct.The sentences in the RESEARCH DESIGN AND METHODS subsection "Statistical analysis," second paragraph (pp.607-608), should read "For individuals progressing to a relevant outcome, the date of exit was set at the midpoint between the first examination where the outcome was identified and the previous examination.This was to account for the fact that progressors will have converted at an unknown time somewhere between these examinations."The calculations were correctly done; that is, the results reported are correct.The online version reflects these changes.
Association News
Authors: William H. Welch
Journal: JAMA (1906)

<h3>Date of Next Session of the American Medical Association.</h3> The next annual session of the American Medical Association will be held at Atlantic City, New Jersey, Tuesday, Wednesday, Thursday and Friday, June 4, 5, 6 and 7, 1907. Atlantic City, Aug. 9, 1906. <h3>To the Members of the American Medical Association:</h3> —A joint meeting of the executive committee of the American Congress of Physicians and Surgeons and of a committee of the Board of Trustees of the American Medical Association was held at Atlantic City, August 8, for the purpose of arranging the dates of the meetings of the two associations so that one should immediately follow the other. After considerable discussion various reasons became known which would seriously interfere with the attendance of the members of either one or the other. It was, therefore, decided that the meeting of the Congress of Physicians and Surgeons should remain as already
Methylphenidate Hallucinosis
Authors: Alexander R. Lucas
Journal: JAMA (1971)

Methylphenidate hydrochloride caused adverse behavioral reactions in three patients. In two instances, a 6 1/2-year-old girl and a 10-year-old boy were receiving therapeutic dosages for hyperkinetic behavior. In the girl, a state of excitement occurred, followed by catatonic withdrawal, while the most prominent feature in the boy was hallucinosis. The third reaction, also hallucinosis, occurred in a 15-year-old girl who had taken an excess of medication. These reactions highlight the importance of close medical supervision of children receiving even relatively safe psychoactive drugs.
"ARTIFICIAL LIGHT THERAPY IN TUBERCULOSIS"
Authors: Edgar Mayer
Journal: JAMA (1924)

<h3>To the Editor:</h3> —Dr. Edgar Mayer, in an otherwise excellent article (The Journal, June 14), continually speaks of radiant energy of wave length shorter than 390 millimicrons as "light." Light is only an interpretation by the brain of stimulation received through the retina and optic nerves by wave lengths of radiant energy lying between 390 millimicrons and 770 millimicrons. Calling an "energy" by the name applied to a sensation is wrong physically and physiologically. The electromagnetic spectrum [which should be called the electromagnetic energium] "is of such a length," says Luckiesh, "that if the visible portion were a foot in length the invisible portion would be many million miles." Ultraviolet and infrared radiations are no more light than roentgen-ray or radio waves. Let us stop talking of invisible light and speak of radiant energy. The misuse of terms in treatment by radiant energy, when various sources are utilized, such as
Capecitabine (X) plus irinotecan (XELIRI) as first-line treatment for metastatic colorectal cancer (MCRC): Final safety findings from a phase II trial
Authors: Y. Z. Patt, J. Liebmann, D. Diamandidis, S. G. Eckhardt, M. Javle, G. R. Justice, W. Keiser, F. C. Lee, W. Miller, E. Lin
Journal: Journal of Clinical Oncology (2004)

3602 Background: The oral fluoropyrimidine X (Xeloda) has superior efficacy and improved safety compared to 5-FU/LV in MCRC. Twice-daily oral X mimics 5-FU infusion and is replacing 5-FU in combination regimens. The efficacy and safety of X plus weekly irinotecan (XELIRI) were evaluated in first-line MCRC. Methods: Recommended doses from two independent phase I trials were: irinotecan 250 mg/m2 i.v. on day 1 plus capecitabine 1000 mg/m2 orally twice-daily on days 1–15, every 3 weeks. Patients (pts) ≥65 years received lower doses of both agents (200 mg/m2 i.v. on day 1 and 750 mg/m2 twice-daily on days 1–15, respectively). Results: Baseline characteristics of the 52 pts enrolled between Oct 2001 and Aug 2003: 29 men, 23 women; median Karnofsky PS 90 (70–100); median age 57.5 (30–79); colon cancer (85%), rectal cancer (11%), both (4%). Tumor differentiation was 15% poor, 63% moderate, 12% well, and 10% unknown. Most common metastatic sites were the liver (77%), lymph nodes (58%), and lung (33%), with 69% of pts having stage IV disease at initial diagnosis. Eleven pts (22%) had received prior adjuvant 5-FU. The median number of treatment cycles is currently 6 (maximum 12 cycles allowed). In the 51 patients evaluable for safety, the most common (>5%) treatment-related grade 3 adverse events were diarrhea (20%), vomiting (16%), dehydration (8%, 1 patient grade 4), nausea (6%), and HFS (6%). Grade 3/4 neutropenia was seen in 26% of pts. There were no treatment-related deaths. Twenty-seven of 44 evaluable pts (61%) showed a response to treatment (1 unconfirmed) and disease control (CR+PR+SD) was achieved in 37 pts (84%). Median time to progression (TTP) and overall survival are currently 6.1 months and 15.6 months, respectively. Conclusions: XELIRI is a highly active and well-tolerated first-line therapy for MCRC. Efficacy compares favorably with previous studies of infusional 5-FU/LV/irinotecan, and safety of XELIRI is comparable to that of FOLFIRI and IFL regimens. Capecitabine should replace 5-FU in combination with irinotecan to create an effective, safe, and convenient treatment option in first-line MCRC. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Hoffmann-La Roche; Novartis Hoffmann-La Roche Hoffmann-La Roche; Lilly; Pfizer; Novartis
Outpatient Trend Continues
Journal: JAMA (1995)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Treatment of psychosocial crises in the emergency service of a general hospital
Authors: F. H. Frankel
Journal: JAMA (1966)

Emergency facilities in metropolitan general hospitals have been facing increasing demands in recent years with a corresponding increase in the number of patients with psychosocial crises. A flexible and multidisciplinary approach to these problems is considered to be the most effective means of handling them and of applying principles of crisis intervention. The ranks of the flexible and assiduous practicing general psychiatrists are the obviously desirable sources of the senior personnel required.
Interventions to Increase Influenza Vaccination of Health-Care Workers—California and Minnesota
Journal: JAMA (2005)

Vaccination of health-care workers (HCWs) has been shown to reduce influenza infection and absenteeism among HCWs, prevent mortality in their patients, and result in financial savings to sponsoring health institutions. However, influenza vaccination coverage among HCWs in the United States remains low; in 2003, coverage among HCWs was 40.1%. This report describes strategies implemented in three clinical settings that increased the proportion of HCWs who received influenza vaccination. The results demonstrate the value of making influenza vaccination convenient and available at no cost to HCWs.
Corticosteroids and Adrenal Function
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 2551: Inhibition of mTOR abrogates mitosis progression
Authors: Hsiao-Hui Kuo, Chieh-Ting Fang, Ling-Huei Yih
Journal: Cancer Research (2019)

Abstract The mammalian target of rapamycin (mTOR) mediates the coordination of cell growth and cell cycle progression in response to nutrient supply. It is frequently activated in cancers and confers resistance to anti-cancer drugs. Accumulated studies have demonstrated that inhibition of mitotic kinases (PLK1 or aurora kinase A) enhances mTOR activities and the mTOR activation is associated with cell survival to anti-mitotic drugs. In this study, whether mTOR signaling is involved in mitosis progression is explored. Treatment of cells with mTOR inhibitors for 24 h resulted in the accumulation of G2 and mitotic cells and increased the percentage of mitotic cells with spindle abnormalities and chromosome missegregation. In addition, mTOR inhibitors sensitized cancer cells to taxol by enhancing apoptosis. Our results indicate that mTOR signaling pathway may be required for faithful mitosis progression and represent a potential resistance mechanism to the use of anti-mitotic drugs. Citation Format: Hsiao-Hui Kuo, Chieh-Ting Fang, Ling-Huei Yih. Inhibition of mTOR abrogates mitosis progression [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2551.
Bile salt toxicity is reduced by ursodeoxycholic acid (UDCA), S-adenosyl-L-methionine (SAMe) and cholesterol availability in cell culture , Internal Medicine, Modena University, Italy
Journal: Hepatology (1995)

Bile acids (BAs) are derived from cholesterol and produced in the liver. The most abundant bile acids in humans are usually conjugated with glycine and taurine and are divided into primary BAs such as cholic acid (CA) and chenodeoxycholic acid (CDCA) and secondary BAs like deoxycholic acid (DCA), lithocholic acid (LCA) and ursodeoxycholic acid (UDCA).The differences amongst individual bile acids (BAs) are significant in order to distinguish different pathological processes and exposure to chemical compounds. Hollow fiber based liquid-phase microextraction (HF-LPME) is a technique that combines sample cleansing, extraction and the concentration of analytes, where a hydrophobic porous capillary membrane is impregnated with an organic extraction solvent and the lumen is filled with microliters of a phase acceptor both organic by nature. The aim of this study was to develop a new method to extract bile acids from plasma through HF-LPME of two phases (octanol as the acceptor phase) using LCMS-IT-TOF. The optimized two-phased LPME procedure for the extraction of bile acids showed limits of detection 1.0 μg L−1 and limits of quantification of 5.0 μg L−1. The intra-assay precision ranged from 2.1 to 11.9%. The method developed was linear over the range of 5.0–200.0 μg L−1 for all analytes. The hollow-fiber liquid-phase microextraction method was applied to human plasma from workers exposed to organic and halogenated solvents and also to unexposed volunteers. The method is simple, low cost and it does not require large amounts of organic solvents, therefore it is quite suitable for the analysis of bile acids exposed to hepatotoxic compounds.